市場調査レポート

医薬品安全監視の世界市場 - 治験段階(臨床前研究、第1相、第2相、第3相、第4相「市販後調査」)および実施機関(社内、外部委託機関)別産業分析、規模、シェア、成長率、動向および予測

Pharmacovigilance Market and Service Providers - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

発行 Transparency Market Research 商品コード 296695
出版日 ページ情報 英文 159 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
医薬品安全監視の世界市場 - 治験段階(臨床前研究、第1相、第2相、第3相、第4相「市販後調査」)および実施機関(社内、外部委託機関)別産業分析、規模、シェア、成長率、動向および予測 Pharmacovigilance Market and Service Providers - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
出版日: 2014年02月28日 ページ情報: 英文 159 Pages
概要

患者への薬剤情報提供をめぐる規制や監査体制の強化およびその火急性が、医薬品安全監視関連市場の成長への影響度を増しています。急性・慢性疾患の増加から医薬品消費が拡大した結果、それに伴って副作用や薬毒による障害が多発するようになりました。また、これらが薬害事件としてメディアを賑わす事態を受け、製薬企業はさまざまな外部機関を利用しながら薬剤の安全性問題に対応しています。

当レポートでは、こうした医薬品安全監視の世界市場に注目し、その動向や背景を治験段階、手法、サービス提供機関および地域別に分析・検証しながら今後の推移を予測するほか、同市場に活躍する主要企業のプロフィールをまとめ、概略以下の構成でお届けします。

第1章 イントロダクション

  • レポートの内容説明
  • 調査方法
  • 市場セグメンテーション

第2章 エグゼクティブサマリー

第3章 医薬品安全監視の世界市場動態

  • イントロダクション
    • 推進要因
      • 薬剤消費数量の増加
      • 重度の障害や死亡につながる薬害事件の頻発
      • リスクを軽減する新技術の採用
      • 拡大する医薬品安全監視サービスの外部機関委託
      • 低コスト地域への製造移転を伴う薬剤開発のグローバリゼーション
    • 抑制要因
      • 厳格で多岐にわたる規制承認手続き
    • 課題
      • 熟練人員の不足
    • Porterのファイブフォース分析:医薬品安全監視の世界市場
    • 医薬品安全監視の世界市場求心力分析 - 地域別

第4章 医薬品安全監視の世界市場 - 治験段階別

  • 概要
    • 臨床前研究
    • 第1相治験
    • 第2相治験
    • 第3相治験
    • 第4相治験(市販後調査)

第5章 医薬品安全監視の世界市場 - 手法別

  • 概要
    • 自発報告
    • 標的報告
    • コホート調査
    • 電子カルテ調査
    • 強化ADR(医薬品副作用)報告

第6章 医薬品安全監視の世界市場 - サービス提供機関別

  • 概要
    • 社内
    • 外部委託

第7章 医薬品安全監視の世界市場 - 地域別

  • 概要
  • 北米
  • 欧州
  • アジア太平洋州
  • その他の地域

第8章 医薬品安全監視の世界市場 - シェア分析

  • 主要各企業の市場シェア

第9章 提言

  • 成功戦略
    • 開発業務受託機関や生命科学事業受託機関との戦略的連合・提携の開発
    • 薬剤安全性の最適化に向けたハブアンドスポークモデル
    • 成果改善に向けた業務活動強化
    • 新興国への市場展開

第10章 企業プロフィール(概要、財務、製品ポートフォリオ、事業戦略など)

図表一覧

目次

A rising tide of regulatory expectations, tougher inspection regime and instant need of patient reporting has provided the much needed impetus for the growth of the pharmacovigilance market. An upsurge in number of acute and chronic diseases has consequently led to a rise in number of drug consumption, which has also elicited a growth in the number of adverse drug events and drug toxicity cases. Moreover, several high-profile safety issues, regulatory warnings, large volume of events to be reviewed along with negative media coverage have compelled the pharmaceutical players to take support of various outsourcing services. There are two major outsourcing services opted by these pharmaceutical players i.e. traditional CROs and BPOs. These outsourcing services not only provide cost savings but also helps in bringing process efficiency. Pharmaceutical companies are now forming long term partnership with the CROs and BPOs to share the costs involved in PV process right from drug discovery to post marketing approvals. In addition, PV requires skilled resources with excellent language skills and strong knowledge pertaining to case reporting.

The research report on pharmacovigilance provides detailed analysis of the global market and helps in understanding the driving forces responsible for the growth of this market. The report discusses the market of pharmacovigilance market on the bases of clinical trials phases i.e. Phase I to III and post marketing surveillance (PMS). We have also mapped the trend for preference of the pharmaceutical players for in-house and outsourcing in our chapter by type of service.

The global pharmacovigilance market has been segmented based on all the above mentioned parameters and market size estimates and forecasts for the period of 2011 to 2019 have been provided for each of the segments, in term of USD million, considering 2012 as the base year for calculations and 2011 representing as the historical year. The CAGR (%) of each market segment for the forecast period 2013 to 2019 has also been provided along with market size estimations.

The report exclusively studies the aforementioned segments with respect to geography. Under geographic section we have covered four regions, namely, North America, Europe, Asia-Pacific and Rest of the World (ROW).

The market overview section gives a detailed qualitative analysis of the factors responsible for driving and restraining the growth of the global pharmacovigilance market. The section also covers opportunities and market attractiveness analysis of the geographical regions.

The report concludes with the competitive landscape and company profiles of major market players. These market players have been profiled on the basis of various attributes such as company overview, financial overview, business strategies, product portfolio and recent developments. Some of the major players profiled in this report include PRA International Inc., Covance Inc., Synowledge LLC, OptumInsight Inc., iMedGlobal, TCS, iGATE Corporation, Cognizant Technology Solutions, Quintiles and others.

Table of Contents

Chapter 1 Introduction

  • 1.1 Report Description
  • 1.2 Research Methodology
  • 1.3 Market Segmentation

Chapter 2 Executive Summary

Chapter 3 Global Pharmacovigilance Market Dynamics

  • 3.1 Introduction
    • 3.1.1 Drivers
      • 3.1.1.1 Rise in number of drug consumption
      • 3.1.1.2 Rise in drug toxicity cases producing significant morbidity and mortality
      • 3.1.1.3 Embracing new technologies to mitigate risk
      • 3.1.1.4 Rise in adoption of pharmacovigilance outsourcing services
      • 3.1.1.5 Globalization of drug development with shift from manufacturing activities from high cost to low cost regions
    • 3.1.2 Restraints
      • 3.1.2.1 Stringent and varied regulatory approval processes
    • 3.1.3 Challenges
      • 3.1.3.1 Lack of availability of skilled labor
  • 3.2 Porter's Five Force Analysis: Global Pharmacovigilance Market
    • 3.2.1 Bargaining Power of Suppliers
    • 3.2.2 Bargaining Power of Buyers
    • 3.2.3 Threat of New Entrants
    • 3.2.4 Threat of Substitutes
    • 3.2.5 Competitive Rivalry
  • 3.3 Market Attractiveness Analysis of the Global Pharmacovigilance Market, by Geography
    • 3.3.1 Market Attractiveness Analysis: Global Pharmacovigilance Market, 2012, by Geography

Chapter 4 Global Pharmacovigilance Market, by Clinical Trial Phases

  • 4.1 Overview
    • 4.1.1 Preclinical Studies
      • 4.1.1.1 Global Preclinical Studies Pharmacovigilance Market Revenue, 2011 - 2019 (USD Million)
    • 4.1.2 Phase I trial
      • 4.1.2.1 Global Clinical Trial Phase I Pharmacovigilance Market Revenue, 2011 - 2019 (USD Million)
    • 4.1.3 Phase II trial
      • 4.1.3.1 Global Clinical Trial Phase II Pharmacovigilance Market Revenue, 2011 - 2019 (USD Million)
    • 4.1.4 Phase III trial
      • 4.1.4.1 Global Clinical Trial Phase III Pharmacovigilance Market Revenue, 2011 - 2019 (USD Million)
    • 4.1.5 Phase IV trial (Post marketing surveillance)
      • 4.1.5.1 Global Clinical Trial Phase IV Pharmacovigilance Market Revenue, 2011 - 2019 (USD Million)

Chapter 5 Global Pharmacovigilance Market, By Type of Methods

  • 5.1 Overview
    • 5.1.1 Spontaneous Reporting
      • 5.1.1.1 Global Spontaneous Drug Safety Reporting Market Revenue, 2011 - 2019 (USD Million)
    • 5.1.2 Targeted Reporting
      • 5.1.2.1 Global Targeted Drug Safety Reporting Market Revenue, 2011 - 2019 (USD Million)
    • 5.1.3 Cohort Event Monitoring
      • 5.1.3.1 Global Cohort Event Monitoring Market Revenue, 2011 - 2019 (USD Million)
    • 5.1.4 EHR Monitoring
      • 5.1.4.1 Global Electronic Health Records (EHR) Monitoring Market Revenue, 2011 - 2019 (USD Million)
    • 5.1.5 Intensified ADR Reporting
      • 5.1.5.1 Global Intensified ADR Reporting Market Revenue, 2011 - 2019 (USD Million)

Chapter 6 Global Pharmacovigilance Market, by Type of Service Providers

  • 6.1 Overview
    • 6.1.1 In-House
      • 6.1.1.1 Global In-House Pharmacovigilance Market Revenue, 2011 - 2019 (USD Million)
    • 6.1.2 Contract Outsourcing
      • 6.1.2.1 Global Contract Outsourcing Pharmacovigilance Market Revenue, 2011 - 2019 (USD Million)

Chapter 7 Global Pharmacovigilance Market, by Geography

  • 7.1 Overview
    • 7.1.1 Comparative Analysis: Global Pharmacovigilance Market, by Geography, 2012 & 2019 (Value %)
  • 7.2 North America
    • 7.2.1 North America Pharmacovigilance Market Revenue, 2011 - 2019 (USD Million)
  • 7.3 Europe
    • 7.3.1 Europe Pharmacovigilance Market Revenue, 2011 - 2019 (USD Million)
  • 7.4 Asia Pacific
    • 7.4.1 Asia-Pacific Pharmacovigilance Market Revenue, 2011 - 2019 (USD Million)
  • 7.5 Rest of the World
    • 7.5.1 Rest of the World Pharmacovigilance Market Revenue, 2011 - 2019 (USD Million)

Chapter 8 Global Pharmacovigilance Market Share Analysis

  • 8.1 Market Share Analysis by Key Players of Global Pharmacovigilance Market
    • 8.1.1 Global CRO Market Share Analysis, by Key Players, 2012 (%)

Chapter 9 Recommendations

  • 9.1 Success Strategies
    • 9.1.1 Developing Strategic Alliances and Partnerships With CROs and Life Science BPOs Companies
    • 9.1.2 Hub and Spoke model to optimize drug safety
    • 9.1.3 Enhancing operational activities for better outcomes
    • 9.1.4 Expand Market into Emerging Countries

Chapter 10 Company Profiles

  • 10.1 Accenture, Plc
    • 10.1.1 Company Overview
    • 10.1.2 Financial Overview
    • 10.1.3 Product Portfolio
    • 10.1.4 Business Strategies
    • 10.1.4.1 Mergers and acquisitions
    • 10.1.5 Recent Developments
  • 10.2 Bristol-Myers Squibb
    • 10.2.1 Company Profile
    • 10.2.2 Financial overview
    • 10.2.3 Product Portfolio
    • 10.2.4 Business Strategies
      • 10.2.4.1 Strategic collaboration
      • 10.2.4.2 Research and Development Initiatives
      • 10.2.4.3 Recent Developments
  • 10.3 Clinquest Group B.V.
    • 10.3.1 Company Overview
    • 10.3.2 Product Portfolio
    • 10.3.3 Business Strategies
      • 10.3.3.1 Strategic partnership
    • 10.3.4 Recent Developments
  • 10.4 Cognizant Technology Solutions
    • 10.4.1 Company Overview
    • 10.4.2 Financial Overview
    • 10.4.3 Product Portfolio
    • 10.4.4 Business Strategies
      • 10.4.4.1 Expansion of geographical footprint
      • 10.4.4.2 Expansion of product portfolio
      • 10.4.4.3 Highly-skilled manpower
      • 10.4.4.4 Strategic acquisitions
    • 10.4.5 Recent Developments
  • 10.5 Covance, Inc.
    • 10.5.1 Company Overview
    • 10.5.2 Financial Overview
    • 10.5.3 Product Portfolio
    • 10.5.4 Business Strategies
      • 10.5.4.1 New product development and innovation
      • 10.5.4.2 Agreements and collaborations
      • 10.5.4.3 Strategic acquisitions
      • 10.5.4.4 Geographical expansion of business
    • 10.5.5 Recent Developments
  • 10.6 GlaxoSmithKline (GSK)
    • 10.6.1 Company Overview
    • 10.6.2 Financial overview
    • 10.6.3 Product Portfolio
    • 10.6.4 Business strategies
      • 10.6.4.1 Research and development initiatives
      • 10.6.4.2 Direct to Consumer Advertising
      • 10.6.4.3 Mergers and acquisitions
    • 10.6.5 Recent developments
  • 10.7 ICON, Plc
    • 10.7.1 Company Overview
    • 10.7.2 Financial Overview
    • 10.7.3 Product Portfolio
    • 10.7.4 Business Strategies
      • 10.7.4.1 Business expansion in APAC region
      • 10.7.4.2 Expansion of services offered
    • 10.7.5 Recent Developments
  • 10.8 iGATE Corporation
    • 10.8.1 Company Overview
    • 10.8.2 Financial Overview
    • 10.8.3 Product Portfolio
    • 10.8.4 Business Strategies
      • 10.8.4.1 Strategic Acquisition
    • 10.8.5 Recent Developments
  • 10.9 iMEDGlobal Corporation
    • 10.9.1 Company Overview
    • 10.9.2 Product Portfolio
    • 10.9.3 Business Strategies
      • 10.9.3.1 Geographical Expansion
    • 10.9.4 Recent Developments
  • 10.10 Infosys
    • 10.10.1 Company Overview
    • 10.10.2 Financial Overview
    • 10.10.3 Product Portfolio
    • 10.10.4 Business Strategies
      • 10.10.4.1 Extensive product portfolio
      • 10.10.4.2 Geographical expansion of business
    • 10.10.5 Recent Developments
  • 10.11 inVentiv Health Inc.
    • 10.11.1 Company Overview
    • 10.11.2 Product Portfolio
    • 10.11.3 Business Strategies
      • 10.11.3.1 Strategic Partnership
      • 10.11.3.2 Strategic Acquisition
    • 10.11.4 Recent Developments
  • 10.12 Johnson and Johnson
    • 10.12.1 Company Profile
    • 10.12.2 Financial Overview
    • 10.12.3 Product Portfolio
    • 10.12.4 Business Strategies
      • 10.12.4.1 Extensive Research and Development Investments
      • 10.12.4.2 Strategic Collaborative Arrangements
      • 10.12.4.3 Recent Developments
  • 10.13 Novartis International AG
    • 10.13.1 Company Overview
    • 10.13.2 Financial Overview
    • 10.13.3 Product Portfolio
    • 10.13.4 Business Strategy
      • 10.13.4.1 Mergers and Acquisitions
    • 10.13.5 Recent Developments
  • 10.14 OptumInsight, Inc.
    • 10.14.1 Company Overview
    • 10.14.2 Product Portfolio
    • 10.14.3 Business Strategies
      • 10.14.3.1 Strategic product launch
      • 10.14.3.2 Strategic collaboration
    • 10.14.4 Recent Developments
  • 10.15 Parexel International Corporation
    • 10.15.1 Company Overview
    • 10.15.2 Financial Overview
    • 10.15.3 Product Portfolio
      • 10.15.3.1 Strong presence in Asia and emerging markets
      • 10.15.3.2 Strategic alliances
      • 10.15.3.3 Mergers & Acquisitions
    • 10.15.4 Recent Developments
  • 10.16 Pfizer, Inc.
    • 10.16.1 Company Overview
    • 10.16.2 Financial Overview
    • 10.16.3 Product Portfolio
    • 10.16.4 Business Strategies
      • 10.16.4.1 Acquisitions
    • 10.16.5 Recent Developments
  • 10.17 Pharmaceutical Product Development, Inc. (PPD, Inc.)
    • 10.17.1 Company Overview
    • 10.17.2 Product Portfolio
    • 10.17.3 Business Strategies
      • 10.17.3.1 Expanding geographic presence
      • 10.17.3.2 Incorporation of innovative technologies
      • 10.17.3.3 Strategic acquisitions
      • 10.17.3.4 New product launch and innovation
    • 10.17.4 Recent Developments
  • 10.18 PRA International, Inc.
    • 10.18.1 Company Overview
    • 10.18.2 Product Portfolio
    • 10.18.3 Business Strategies
      • 10.18.3.1 Mergers and acquisitions
    • 10.18.4 Recent Developments
  • 10.19 Quantum Solutions India
    • 10.19.1 Company Overview
    • 10.19.2 Product Portfolio
    • 10.19.3 Business Strategies
      • 10.19.3.1 Strategic Collaborations
  • 10.20 Quintiles Transnational Corporation
    • 10.20.1 Company Overview
    • 10.20.2 Financial Overview
    • 10.20.3 Product Portfolio
    • 10.20.4 Business Strategies
      • 10.20.4.1 Expansion of services
      • 10.20.4.2 Acquisitions and partnerships
      • 10.20.4.3 Innovation in services offered
    • 10.20.5 Recent Developments
  • 10.21 F. Hoffmann-La Roche Ltd.
    • 10.21.1 Company Overview
    • 10.21.2 Financial Overview
    • 10.21.3 Product Portfolio
    • 10.21.4 Business Strategies
      • 10.21.4.1 Licensing Agreement
      • 10.21.4.2 Product portfolio expansion
  • 10.22 Sanofi Aventis
    • 10.22.1 Company Overview
    • 10.22.2 Financial Overview
    • 10.22.3 Product Portfolio
    • 10.22.4 Business Strategy
      • 10.22.4.1 Renewal of cooperation protocol
      • 10.22.4.2 Recent developments
  • 10.23 Synowledge LLC
    • 10.23.1 Company Overview
    • 10.23.2 Product Portfolio
    • 10.23.3 Business Strategies
      • 10.23.3.1 Geographical Expansion
      • 10.23.3.2 Strategic Partnership
    • 10.23.4 Recent Developments
  • 10.24 United BioSource Corporation
    • 10.24.1 Company Overview
    • 10.24.2 Product Profiling
    • 10.24.3 Business Strategies
      • 10.24.3.1 Strategic acquisitions
  • 10.25 Wipro Limited
    • 10.25.1 Company Overview
    • 10.25.2 Financial Overview
    • 10.25.3 Product Portfolio
    • 10.25.4 Business Strategies
      • 10.25.4.1 Geographical expansion

List of Figures

  • FIG. 1 Drug Safety From Molecule to Market
  • FIG. 2 Global Pharmacovigilance : Market Segmentation
  • FIG. 3 Global Pharmacovigilance Market, by Type of Service Providers, 2012 (USD Million)
  • FIG. 4 Global Pharmacovigilance Market, by Type of Clinical Trial Phases, 2012 (USD Million)
  • FIG. 5 Global Pharmacovigilance Market, by Type of Methods, 2012 (USD Million)
  • FIG. 6 Global Pharmacovigilance Market: Drivers and Restraints
  • FIG. 7 Porter's Five Force Analysis: Global Pharmacovigilance Market
  • FIG. 8 Market Attractiveness Analysis: Global Pharmacovigilance Market, 2012, by Geography
  • FIG. 9 Safety Services : Product Lifecycle
  • FIG. 10 Global Preclinical Studies Pharmacovigilance Market Revenue, 2011 - 2019 (USD Million)
  • FIG. 11 Global Clinical Trial Phase I Pharmacovigilance Market Revenue, 2011 - 2019 (USD Million)
  • FIG. 12 Global Clinical Trial Phase II Pharmacovigilance Market Revenue, 2011 - 2019 (USD Million)
  • FIG. 13 Global Clinical Trial Phase III Pharmacovigilance Market Revenue, 2011 - 2019 (USD Million)
  • FIG. 14 Global Clinical Trial Phase IV Pharmacovigilance Market Revenue, 2011 - 2019 (USD Million)
  • FIG. 15 Comparison of Methods: Pharmacovigilance reporting
  • FIG. 16 Global Spontaneous Drug Safety Reporting Market Revenue, 2011 - 2019 (USD Million)
  • FIG. 17 Global Targeted Drug Safety Reporting Market Revenue, 2011 - 2019 (USD Million)
  • FIG. 18 Global Cohort Event Monitoring Market Revenue, 2011 - 2019 (USD Million)
  • FIG. 19 Global Electronic Health Records (HER) Monitoring Market Revenue, 2011 - 2019 (USD Million)
  • FIG. 20 Global Intensified ADR Reporting Market Revenue, 2011 - 2019 (USD Million)
  • FIG. 21 End-to-End Safety Across the Lifecycle
  • FIG. 22 Global In-House Pharmacovigilance Market Revenue, 2011 - 2019 (USD Million)
  • FIG. 23 Global Contract Outsourcing Pharmacovigilance Market Revenue, 2011 - 2019 (USD Million)
  • FIG. 24 Comparative Analysis: Global Pharmacovigilance Market, by Geography, 2012 & 2019 (Value %)
  • FIG. 25 North America Pharmacovigilance Market Revenue, 2011 - 2019 (USD Million)
  • FIG. 26 Europe Pharmacovigilance Market Revenue, 2011 - 2019 (USD Million)
  • FIG. 27 Asia-Pacific Pharmacovigilance Market Revenue, 2011 - 2019 (USD Million)
  • FIG. 28 Rest of the World Pharmacovigilance Market Revenue, 2011 - 2019 (USD Million)
  • FIG. 29 Global CRO: Market Share, by Key Players, 2012 (%)
  • FIG. 30 Accenture, Plc.: Annual Revenue (USD Billion) 2010 - 2012
  • FIG. 31 Bristol-Myers Squibb: annual sales revenue, USD million, 2010 - 2012
  • FIG. 32 Cognizant Technology Solutions: Annual Sales Revenue, USD Million (2010- 2012)
  • FIG. 33 COVANCE, Inc.: Annual Sales Revenue, USD Billion (2010- 2012)
  • FIG. 34 GSK, Annual Sales Revenue, 2010 - 2012 (USD million) (Conversion rate: 1 GBP = 1.6651 USD)
  • FIG. 35 ICON, PLC: Annual Sales Revenue, USD Million (2010- 2012)
  • FIG. 36 iGATE Corporation, Annual Revenue: 2010 - 2012 (USD Million)
  • FIG. 37 Infosys: Annual Sales Revenue, USD Million (2010- 2012)
  • FIG. 38 Johnson and Johnson: annual sales revenue, USD million, 2010 - 2012
  • FIG. 39 Novartis International AG., Annual Sales: 2010 - 2012 (USD Million)
  • FIG. 40 Parexel International Corporation: Annual Sales Revenue, USD Million (2010- 2012)
  • FIG. 41 Pfizer, Inc.: Annual Revenue, 2010 - 2012 (USD Million)
  • FIG. 42 Quintiles Transnational Corporation: Annual Sales Revenue, USD Billion (2010- 2012)
  • FIG. 43 F. Hoffmann-La Roche Ltd., Annual Revenue: 2010 - 2012 (USD Million) (1 CHF = 1.09 USD)
  • FIG. 44 Sanofi: Annual Sales Revenue, 2010 - 2012 (USD million)
  • FIG. 45 Wipro Limited: Annual Revenue (USD Million) 2010 - 2012

List of Tables

  • TABLE 1 Market Snapshot : Pharmacovigilance Market
  • TABLE 2 List of Drugs Withdrawn Recently:
  • TABLE 3 Global Pharmacovigilance Market Revenue, By Type of Clinical Trial Phases, 2011 - 2019 (USD Million)
  • TABLE 4 Global Pharmacovigilance Market Revenue, By Type of Methods, 2011 - 2019 (USD Million)
  • TABLE 5 Global Pharmacovigilance Market Revenue, By Type of Service Providers, 2011 - 2019 (USD Million)
  • TABLE 6 Global Pharmacovigilance Market Revenue, By Geography, 2011 - 2019 (USD Million)
Back to Top